Categories: All postsCannabis

Flower One Holdings is a double, Mackie Research says

Mackie Research analyst Greg McLeish says completing a new financing round will help US cannabis company Flower One Holdings (Flower One Holdings Stock Quote, Chart CSE:FONE) execute to plan.

In a coverage resumption on Monday, the analyst reiterated his “Buy” rating while lifting his price target from C$4.50 to C$5.50 per share, representing a projected return of 108 per cent at the time of publication.

Nevada-based Flower One announced on March 28 the closing of a C$50-million offering of convertible debenture units (the company further announced on Monday the full exercise of the over-allotment option of an additional C$7.5 million in proceeds).

The company says that the funds will go towards expansion of its operations in Nevada, namely, the retrofitting of its NLV Greenhouse in North Las Vegas, the repayment of a vendor note in connection with its purchase of NLV Organics, the strengthening of its branding and retail strategies and other working capital expenses.

In his note to clients, McLeish stresses that Nevada is currently developing a robust cannabis industry, while across the United States, industry dynamics are “very compelling.”

“Once these [US] companies achieve economies of scale and improve operational efficiencies, they should be able to generate EBITDA margins in excess of 30 per cent,” says McLeish.

“The closing of the C$50 mm convertible debenture financing will allow Flower One to execute on its business plan and the recently announced licensing agreements and brand partnerships will help to underpin our financial forecasts through 2020. As a result, we are increasing our target multiple on Flower One to 10.0x EV/EBITDA (previously 8.0x),” he says.

McLeish expects FONE to generate fiscal 2018 revenue and EBITDA of $241,000 and negative $4.2 million, respectively, fiscal 2019 revenue and EBITDA of $134.9 million and $45.1 million, respectively, and fiscal 2020 revenue and EBITDA of $251.1 million and $90.1 million, respectively.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: fone
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Magellan Aerospace stock a buy?

Its first quarter results are in the books and Paradigm Capital analyst J Marvin Wolff thinks there is money to… [Read More]

9 hours ago

Phunware is undervalued, Roth says

Ahead of the company's first quarter results, Roth MKM analyst Darren Aftahi thinks there is money to be made on… [Read More]

10 hours ago

Héroux-Devtek is a buy, Desjardins says

Ahead of the company's quarterly results, Desjardins Securities analyst Benoit Poirier likes what he sees from Héroux-Devtek (Héroux-Devtek Stock Quote,… [Read More]

11 hours ago

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

1 day ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

1 day ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

1 day ago